Bejel laboratory findings: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(8 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Bejel}}
{{Bejel}}
Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


{{CMG}}
{{CMG}}
==Overview==
==Laboratory Findings==
==Laboratory Findings==
 
===Syphilis Serology===
Nontreponemal (reagin) Test
====Nontreponemal (reagin) Test====
 
* Treponemal (specific) Test
* Treponemal (specific) Test
* Rapid plasma reagin (RPR) test
* [[Rapid plasma reagin]] ([[RPR]]) test
* Venereal Disease Research Laboratory (VDRL) test
* Venereal Disease Research Laboratory (VDRL) test
* Toluidine red unheated serum test (TRUST)
* [[Toluidine red unheated serum test]] ([[TRUST]])


Treponemal (specific) Test
====Treponemal (specific) Test====
* Rapid plasma reagin (RPR) test
* Rapid plasma reagin (RPR) test
* Venereal Disease Research Laboratory (VDRL) test
* Venereal Disease Research Laboratory (VDRL) test
* Toluidine red unheated serum test (TRUST)
* Toluidine red unheated serum test (TRUST)
* Fluorescent treponemal antibody-absorption (FTA-ABS) test
* [[Fluorescent treponemal antibody-absorption]] ([[FTA-ABS]]) test
* Treponema pallidum immobilization (TPI) test
* Treponema pallidum immobilization ([[TPI]]) test
* Treponema pallidum particle agglutination assay (TPPA)
* Treponema pallidum particle agglutination assay (TPPA)
* Enzyme immune assay (EIA) or enzyme-linked immunosorbent assay (ELISA)
* Enzyme immune assay ([[EIA]]) or enzyme-linked immunosorbent assay (ELISA)
* Chemiluminescence immunoassay
* [[Chemiluminescence immunoassay]]
* Chromatographic point of contact (POC) tests
* Chromatographic point of contact (POC) tests
===Syphilis Serology===
 
Serologic tests for syphilis include screening tests that use nonspecific cardiolipin antigens and confirmatory tests that use specific T. pallidum antigens (Table 1). A nontreponemal test such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR) or an equivalent test may be used for screening. Positive results on these nontreponemal tests should be confirmed by using a treponemal test, such as fluorescent treponemal antibody absorption (FTA-ABS) or other treponemal test.
Serologic tests for [[syphilis]] include screening tests that use nonspecific cardiolipin antigens and confirmatory tests that use specific T. pallidum antigens (Table 1). A nontreponemal test such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR) or an equivalent test may be used for screening. Positive results on these nontreponemal tests should be confirmed by using a treponemal test, such as fluorescent treponemal antibody absorption (FTA-ABS) or other treponemal test.


Screening tests such as the VDRL and RPR are relatively simple to perform and provide rapid results. However, interpretation of results demands trained personal. In addition, laboratory equipment and quality control can present challenges in non-U.S. settings. Both VDRL and RPR quantitative titer usually correlate with disease activity and are used to monitor the effect of treatment. If treatment is successful, the antibody titer gradually declines. A fourfold change in titer (e.g., from 1:16 to 1:4) is necessary to demonstrate a clinically significant difference between two nontreponemal tests. Sequential serologic tests in individuals should be performed by using the same testing method, because quantitative results from the two tests cannot be compared directly; RPR titers are frequently slightly higher than VDRL titers. The timing of follow-up testing is dictated by the clinical presentation and the stage of infection, as well as the HIV status of the refugee, and are detailed in the current treatment guidelines
Screening tests such as the VDRL and RPR are relatively simple to perform and provide rapid results. However, interpretation of results demands trained personal. In addition, laboratory equipment and quality control can present challenges in non-U.S. settings. Both VDRL and RPR quantitative titer usually correlate with disease activity and are used to monitor the effect of treatment. If treatment is successful, the antibody titer gradually declines. A fourfold change in titer (e.g., from 1:16 to 1:4) is necessary to demonstrate a clinically significant difference between two nontreponemal tests. Sequential serologic tests in individuals should be performed by using the same testing method, because quantitative results from the two tests cannot be compared directly; RPR titers are frequently slightly higher than VDRL titers. The timing of follow-up testing is dictated by the clinical presentation and the stage of infection, as well as the HIV status of the refugee, and are detailed in the current treatment guidelines
Unlike nontreponemal tests, treponemal tests (e.g., FTA) do not usually revert to nonreactivity after successful treatment of syphilis. Screening with treponemal tests (i.e., use of rapid syphilis tests) is not recommended in high-prevalence settings, because these tests will be reactive in persons with previous successful treatment as well as those with untreated or incompletely treated infection. Therefore, treatment of persons with treponemal positive tests, without previous positive nontreponemal testing (i.e. VDRL, RPR), may result in overtreatment.
Unlike nontreponemal tests, treponemal tests (e.g., FTA) do not usually revert to nonreactivity after successful treatment of syphilis. Screening with treponemal tests (i.e., use of rapid syphilis tests) is not recommended in high-prevalence settings, because these tests will be reactive in persons with previous successful treatment as well as those with untreated or incompletely treated infection. Therefore, treatment of persons with treponemal positive tests, without previous positive nontreponemal testing (i.e. VDRL, RPR), may result in overtreatment.
==References==
==References==
{{reflist|2}}
{{reflist|2}}
Line 35: Line 33:
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Infectious skin diseases]]
[[Category:Needs content]]
[[Category:Needs content]]
[[Category:Needs overview]]

Latest revision as of 17:11, 18 September 2017

Bejel Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating Bejel from other Diseases

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Bejel laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bejel laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bejel laboratory findings

on Bejel laboratory findings

Bejel laboratory findings in the news

Blogs on Bejel laboratory findings

Directions to Hospitals Treating Bejel

Risk calculators and risk factors for Bejel laboratory findings

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Laboratory Findings

Syphilis Serology

Nontreponemal (reagin) Test

Treponemal (specific) Test

  • Rapid plasma reagin (RPR) test
  • Venereal Disease Research Laboratory (VDRL) test
  • Toluidine red unheated serum test (TRUST)
  • Fluorescent treponemal antibody-absorption (FTA-ABS) test
  • Treponema pallidum immobilization (TPI) test
  • Treponema pallidum particle agglutination assay (TPPA)
  • Enzyme immune assay (EIA) or enzyme-linked immunosorbent assay (ELISA)
  • Chemiluminescence immunoassay
  • Chromatographic point of contact (POC) tests

Serologic tests for syphilis include screening tests that use nonspecific cardiolipin antigens and confirmatory tests that use specific T. pallidum antigens (Table 1). A nontreponemal test such as Venereal Disease Research Laboratory (VDRL), rapid plasma reagin (RPR) or an equivalent test may be used for screening. Positive results on these nontreponemal tests should be confirmed by using a treponemal test, such as fluorescent treponemal antibody absorption (FTA-ABS) or other treponemal test.

Screening tests such as the VDRL and RPR are relatively simple to perform and provide rapid results. However, interpretation of results demands trained personal. In addition, laboratory equipment and quality control can present challenges in non-U.S. settings. Both VDRL and RPR quantitative titer usually correlate with disease activity and are used to monitor the effect of treatment. If treatment is successful, the antibody titer gradually declines. A fourfold change in titer (e.g., from 1:16 to 1:4) is necessary to demonstrate a clinically significant difference between two nontreponemal tests. Sequential serologic tests in individuals should be performed by using the same testing method, because quantitative results from the two tests cannot be compared directly; RPR titers are frequently slightly higher than VDRL titers. The timing of follow-up testing is dictated by the clinical presentation and the stage of infection, as well as the HIV status of the refugee, and are detailed in the current treatment guidelines Unlike nontreponemal tests, treponemal tests (e.g., FTA) do not usually revert to nonreactivity after successful treatment of syphilis. Screening with treponemal tests (i.e., use of rapid syphilis tests) is not recommended in high-prevalence settings, because these tests will be reactive in persons with previous successful treatment as well as those with untreated or incompletely treated infection. Therefore, treatment of persons with treponemal positive tests, without previous positive nontreponemal testing (i.e. VDRL, RPR), may result in overtreatment.

References

Template:WH Template:WS